GE HealthCare Technologies Inc. - Common Stock (GEHC)
78.24
+1.79 (2.34%)
NASDAQ · Last Trade: Nov 25th, 3:14 AM EST
Detailed Quote
Previous Close
76.45
Open
76.51
Bid
76.25
Ask
78.00
Day's Range
76.51 - 79.02
52 Week Range
57.65 - 94.80
Volume
7,178,297
Market Cap
35.52B
PE Ratio (TTM)
16.17
EPS (TTM)
4.8
Dividend & Yield
0.1400 (0.18%)
1 Month Average Volume
4,647,844
Chart
About GE HealthCare Technologies Inc. - Common Stock (GEHC)
GE HealthCare Technologies Inc. is a leading global medical technology and digital solutions innovator focused on improving patient outcomes through advanced healthcare solutions. The company develops and manufactures a wide range of diagnostic imaging systems, monitoring devices, and healthcare IT services that empower healthcare providers to deliver accurate and efficient patient care. Through its commitment to innovation, GE HealthCare supports clinicians and patients by providing tools that enhance diagnostic capabilities, streamline workflows, and facilitate data-driven decision-making in an increasingly complex healthcare environment. Read More
The Board of Directors of GE HealthCare Technologies Inc. (Nasdaq: GEHC) today declared a cash dividend of $0.035 per share of Common Stock for the fourth quarter of 2025 payable on February 13, 2026, to all shareholders of record as of January 9, 2026.
Paris, France – November 24, 2025 – French medtech innovator AI-Stroke has successfully closed a substantial US$4.6 million seed funding round, a pivotal step in advancing its groundbreaking artificial intelligence technology aimed at transforming pre-computed tomography (CT) stroke triage. Announced on November 18, 2025, this significant investment underscores a growing confidence in AI-driven solutions to [...]
GE HealthCare today announced the submission of a 510(k) to the U.S. FDA seeking clearance for Photonova™ Spectra,i its new photon-counting computed tomography (PCCT) system with advanced AI algorithmsii – marking a major milestone in the company’s decades-long history of CT innovation. Built on GE HealthCare’s proprietary Deep Silicon detector technology, Photonova Spectra is designed to deliver remarkable spectral and spatial resolution for ultra-high-definition (UHD) imaging with wide coverage, seeking to enable fast acquisition speeds, precise visualization of anatomical structures and enhanced material separation.
Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors.
However, their sheer size makes it more challenging to maintain high growth rates as they’ve already captured significant portions of their markets.
GE HealthCare (Nasdaq: GEHC) announced it has entered into an agreement to acquire Intelerad, a leading medical imaging software provider for the healthcare industry, for a purchase price of $2.3 billion paid in cash. This acquisition demonstrates GE HealthCare’s continued commitment to cloud-enabled and AI-powered solutions across care settings and furthers the company’s aim to triple its offerings of cloud-enabled products by 2028.
In a pivotal shift for artificial intelligence in healthcare, researchers and developers are increasingly focusing on the reliability and diagnostic accuracy of AI methods for processing medical images, moving decisively beyond mere aesthetic quality. This re-prioritization underscores a maturing understanding of AI's critical role in clinical settings, where the stakes are inherently high, and trust [...]
GE HealthCare (Nasdaq: GEHC) today announced that Cardiovascular Associates of America (CVAUSA), the largest network of private cardiology groups in the U.S., plans to broaden its adoption of GE HealthCare’s FDA-approved cardiac positron emission tomography (PET) radiotracer Flyrcado™ (flurpiridaz F 18) injection, across approximately 25 sites following a successful pilot at Cardiovascular Medicine in Davenport, Iowa. This planned rollout marks a significant milestone for advancing PET myocardial perfusion imaging (MPI) in community cardiology settings and reflects growing confidence in Flyrcado’s role in shaping the future of cardiac imaging.
Recent breakthroughs in multimodal Artificial Intelligence (AI) are fundamentally reshaping the landscape of cancer research, ushering in an era of unprecedented precision in diagnosis and personalized treatment. By intelligently integrating diverse data types—from medical imaging and genomic profiles to clinical notes and real-world patient data—these advanced AI systems offer a holistic and nuanced understanding of [...]
GE HealthCare’s third quarter saw revenue and adjusted profit come in slightly above Wall Street’s expectations, but the market reacted negatively, reflecting concerns about margin pressures. Management pointed to strong demand across imaging and pharmaceutical diagnostics as primary drivers, with robust orders growth and new enterprise deals contributing to a healthy backlog. However, increased tariffs and a product hold in Patient Care Solutions weighed on profitability. CEO Peter Arduini noted, “We delivered robust orders growth of 6% with growth across all segments,” while CFO Jay Saccaro highlighted that tariff impacts reduced adjusted EBIT margin by 180 basis points, partially offset by volume and pricing gains.
Even if a company is profitable, it doesn’t always mean it’s a great investment.
Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, limiting growth.
This has capped returns as the industry’s six-month gain of 9.8% has lagged the S&P 500’s 22.6% climb.
Healthcare technology company GE HealthCare Technologies (NASDAQ:GEHC) beat Wall Street’s revenue expectations in Q3 CY2025, with sales up 5.8% year on year to $5.14 billion. Its non-GAAP profit of $1.07 per share was 2.2% above analysts’ consensus estimates.
GE HealthCare Q3 earnings beat estimates as sales rise 6% and orders grow 6% organically, prompting a raised full-year profit outlook despite tariff costs.
Healthcare technology company GE HealthCare Technologies (NASDAQ:GEHC) reported Q3 CY2025 results exceeding the market’s revenue expectations, with sales up 5.8% year on year to $5.14 billion. Its non-GAAP profit of $1.07 per share was 2.2% above analysts’ consensus estimates.
Healthcare technology company GE HealthCare Technologies (NASDAQ:GEHC)
will be announcing earnings results this Wednesday before market hours. Here’s what investors should know.
